ANGO - Earnings call transcript Q1 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the AngioDynamics Fiscal Year 2020 First Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

The news release detailing the fiscal 2020 first quarter results crossed the wire earlier this morning, and is available on the Company’s website. also section live at of is at the www.angiodynamics.com. call Investors the the conference being over broadcast Internet This Company’s website at today’s call. And will one of replay after the available hour of the approximately same end the the site webcast be call

this you the I or the to of events or which for forward-looking cause the statements. about future forward-looking including call, XX-Q review filings the we may statements Company’s the past begin, in results listeners expected during XX-K, will Management encourages SEC, Company's to XXXX. statements and earnings, future year margins differ like regarding and fiscal identify with would Before the that actual limitation, specific and materially factors including revenue, from caution Company to without the described that course conference projections forms gross adjusted make those events,

also Investors Company's under morning's slide offering conjunction results and insight into call. the read the be press Presentations. Company's with performance during website financial financial results conference Company's the in the the release available is Events presentation should of discussing A operating on This & this package section

to Executive Clemmer, to call the President and AngioDynamics' Chief like over now Officer. I'd turn Clemmer? Mr. Jim

Jim Clemmer

and Thank XXXX us for first thank morning, AngioDynamics’ good you, you Rob, fiscal quarter And everyone. for joining earnings call.

the of an President today's quarter. Joining for overview analysis Greiner, quarter Financial first operating Chief and and Vice begin who performance. is by Officer like me execution provide But Executive of to providing call detailed our on AngioDynamics’ first, financial will a Michael highlights our I'd

year progress longer have additional Company And performance, during significantly one from vastly the will financial quarter. term strategic AngioDynamics look today did made our year towards I and am does pleased with today. our a as it well than very than as different looks ago. different the now, vision it achieving the we operational solid

that technologies acquiring management and efforts complement to thrombus on focus innovative are developing platforms. our continuing our We and oncology

to number development fiscal Additionally, new release and a research products a us. and for top during priority track of extensions on remains XXXX. remain We product

may term In evaluate that longer strategy. addition, we divesting vision portfolio our no to of businesses and align longer with consider our existing continue and

NAMIC us divestiture continue our to late announced fiscal well XXXX on example, front, as For business as to we invest evidenced internally acquisition the the in be of to by the allows this aggressively as M&A that morning. opportunistic

The to it’s with laser large within with and acquisition highly of to in therapy our strategy is complement established innovative well-positioned is our growing and technologies Eximo of a take AngioVac share a consistent disruptive great platform. vein-focused and that reimbursement dynamics. a differentiated is space, clotting Medical acquiring technology Eximo’s Limited stated market the atherectomy

currently the significant is in over is coming And as to limited an building will our stage, commercial this quarters portfolio. addition technology while support it product market. fully we This a achieve will believe growth product trajectory sales be the organization the we to significant penetrates launch this a exciting and

to making addition To significant overall prepared invest its in are to the enter this markets. potentially in growth support to that we by opportunities owning investments, additional presented future product are platform

compared $X.XX. are a And range have release, to in $X.XX years current of to EPS XXXX. outcomes We expectations earnings impact year will adjusted noted modifying year better a to over improved clinicians revenue in as as Eximo anticipate we their current the use our material not understanding afforded fiscal by gain increase this begin in for the technology, state we a ease of of of a coming care. to our meaningful and revenue

will devices. in is see And use the than other to a that in to including other enables technology more versatile laser perform atherectomy product. novel clinicians methods, easier clinicians atherectomy value and laser that way we're this This confident

million $XX milestones. totaling and million We’re associated revenue with Eximo upfront paying technical earn-outs $XX in additional with consideration for

NanoKnife. to now Turning

our continued study up achieving end secured is study. sites momentum seven of line IRB reported XX approval Our our our additional to -- year. DIRECT by continues we sites related as momentum This And have anticipate previously to IRB our expectations. the with approval fiscal in

over with quarters. Separately, look on we by are forward this to additional updates that providing NanoKnife-related complete us end working year. safety both the these will sites exciting prostate to We of the you study the enable studies coming our of fiscal

week, with which XXXX. mentioned track launch combination I will efforts products R&D extensions product remain our of of AngioVac, efficiency, will version earlier, a key improve development further We fiscal an portfolio. and improved enable will thrombus introductions, that for stone shapes a include to utilizing which As be device’s us product in the last cannula was these stepping on new new within and management launched the

in dual has already Vortex generator, during three Our that products which units been launched the ports body new portfolio. our technology, and our also new acute a portfolio, access well combines dialysis BioFlo triple that NanoKnife lumen vascular catheters our And as X.X including expand new with with first quarter. our as port two sold catheter will

announced to well agreements groups. U.S. Premier’s We're X,XXX this ASCEND of infusion port approximately access and the We portfolio also supply us purchasing XXX,XXX to dual-source network and a extensive while provides hospitals of two SURPASS agreement products. Xcela, recently implantable membership by our ports, sole-source as validating as further including Premier excited quality Vortex high other membership as BioFlo, announcement, group it and with providers, with committed

I am ongoing operational our very pleased with improvements.

on Our our initiatives. team make to progress continues outstanding strategic

holds what about excited for AngioDynamics. very are future the We

we We growth. this $XXX exhibiting recent that Finally, market M&A entered by moderate now, An announced and is us acquisition to in play management with solutions oncology as divestiture to and focus of to thrombus fluid market continue example attractive we that on already the Eximo exited our our executing markets. a million we've efforts allow $XXX a business. mature management slow the strategy will R&D of our And stated, I've morning. highlighted million growing plus

to I'd Executive that, Chief With to over like Michael call and Financial our President Greiner, the turn Vice Officer.

Michael Greiner

morning, good and Jim, everyone. Thanks,

we Investor comparisons remember key post financial all presentation the from quarterly a year. items summarizing Relations otherwise that please I Before exclude Fluid with year-end guidance. prior associated our year results our as contribution the our and Unless on business well Management and website, our noted, the as results, begin, of NAMIC prior

BioSentry first X.X% on X% net for quarter of fiscal million, an and RadiaDyne $XX decline representing organic acquisitions, growth basis. the Our including sales XXXX were of when and our year-over-year

was from growth of the XXXX, first year Excluding the representing X.X%. contribution during our fiscal Asclera quarter XXXX revenue X.X%, of organic which fourth fiscal for stopped the quarter distributing revenue we product, growth

excluding our well. the On These growth thrombolytic basis, quarter. dialysis and or products to solid by AngioVac venous exhibited an catheter offset were products declines growth of products organic our when growth returned Separately, in as PICCs Ports pockets Asclera. during and insufficiency

to BioSentry prior specifically Alatus the acquisitions, our balloon Sealant IsoLoc and continue traction around and year System We Tract the see products.

We have marketplace. OARtrac our this ensuring still not go-to-market strategy proper appropriate yet seen in technology and and the to system for the revenue related determining long-term meaningful are acceptance of

slight our ex X.X%. and in thrombolytic slight Our AngioVac in total venous as a Asclera excluding grew products partially were as and products core by Strong Asclera in growth business. decline growth offset VIT well X.X% our our grew business year-over-year,

our XX% validate our of within in current and volume during quarter year-over-year, September, acquire to the that products of representing over completed our to complex procedures with AngioVac procedural eighth VIT the than volume share strategy double-digit cases and to will our build month moderately excited Turning remained products. fill complementary within AngioVac portfolio, to Also, our our continues consecutive I'm revenue growth strong with gap increasing or more XXX ever first completed XXX platform. thrombus we cases that month with

strong in and during sales growth offset declined of as quarter sales midlines of continued by PICCs revenue declines the performance in products our Vascular first Ports. access and in was roughly X.X% dialysis

primarily XX.X%, Revenue products. sales Ablation as as growth from our year and in was by from prior decline offset acquisitions, the growth our continued well oncology anticipated related of This to Radiofrequency business Solero. NanoKnife partially increased

statement. Now, moving income down the

to first by year basis XX.X%, Our as gross productivity well a XXXX margin mix. as improvements supply driven fiscal ago, and for product the up XXX points chain of was positive compared quarter

during sales year or or expenses million a development ago. the quarter first $X.X fiscal of sales were and to of XX.X% million XXXX research $X.X X.X% compared Our of

invest technologies. a million acquisition We strategic previously have are and R&D be we spend and now growth Eximo. of investments core to in we As as our to clinical related $XX between continuing in expect to year million to messaged, XXXX of result our R&D support of the $XX fiscal

year as anticipate of be the for $XX.X $XX.X representing million, sales release expense XXXX. of for million, to product of XX% This year that the XX.X% Eximo our fiscal the sales, required as well ago. compared launches million will investments this the increased in of acquisition discussed Eximo to and Jim first between $XXX of Inclusive of in $XXX SG&A for SG&A we XXXX market full support representing million fiscal fiscal to half a year. spend, earlier, quarter back increase upcoming spend a

the cash for income quarter share in $X.XX we flow of adjusted year. share fiscal year. of fiscal quarter million the fiscal used the $X.X of EBITDAS the operating quarter quarter quarter And $X.X compared income first in XXXX, Adjusted last net per or to $X.X adjusted first was per our million was the was first of negative XXXX while last $X.XX million or first $X.X net our of of activities, in first million, cash And free compared XXXX to million in $X.X of in million. $X.X

$XXX.X and cash detailed divestiture. May had following began a August quarter for roughly We to between refer with NAMIC XXst the our million five description slide XXst. cash, walk outlays the we on in and Please material

no As debt. $XX.X cash XXXX, in of cash and had million XX, equivalents we August and

As million of and in no approximately cash have announced $XX.X equivalents of today, outstanding acquisition still and the Eximo, cash debt. post we

$XXX of our the to Eximo which morning, in the in for the regards and of this net With XX% continue XX%. million, $XXX of to includes impact fiscal expect announced gross sales range XXXX, million we acquisition to range margin to guidance financial the

mentioned, anticipate range investment to required Eximo support as this that $X.XX in our year adjusted EPS now is the the footprint also aforementioned out $X.XX, to of build our which, We to Jim commercial contemplates acquisition.

like open questions. that, to for the the to call operator to call With the I'd turn back

Operator

Please proceed conducting now line Our We'll session. Mishan [Operator with question your with Matthew first be KeyBanc. you. from question-and-answer comes question. the Thank of Instructions] a

Matthew Mishan

my standalone for Thank Hey, and need why have a does people currently? sales do Jim, Great. they how many force, sales taking you Eximo questions.

Jim Clemmer

question. morning. good Matt, Good

the During labs, Eximo sales where procedures over the process sell number a will a in a you we dual today, of aspect. office-based used lot products as of know kind be approached are the of our performed. today of months, that we diligence last with lot Because it

force. to Eximo our have So, those sales physicians our and sales our are dedicated bag comfortable with today. least we After way we this current felt standalone products, adding of a quality value sales market, looked force these our at the doing We dedicated Company to initially, our is or the at unique diligence, users. technology a best the to approach communicating having

We We’re make today. start it stand itself with also, of Matt, has four team. the a those believe novel. users technology clearly rendering communicate based we competitors know, so this to good on and and value product dedicated you support unique wanted a new to its why that sure market, we as it's But alone also will

Matthew Mishan

with -- how many how this did start sales acquisition And off this with? come did then, people many to

Jim Clemmer

strong a met footprint. buying very They've an job to this strong brilliant amazing a technology. have job we great special. enable us done such little really, that wait folks to with This can't developing people. startup and is commercial the so work scientists We on an show it structure. or to we're they've also more with clinical has less was market a really When why matchup. It's pathway and laser. at go a world They the technology Eximo, unique that really regulatory really, indications done it’s amazing claim the really why Matt,

met when Now, what other. they didn't we do team. That's commercial out each really a is build

value well, having understanding commercial of experience. knowing market, have we the good ICs the this So, and

good really Matt, looking, go really a and as they really, for weren't good them, for it's well. But, acquisition; it. So, a us, it's partnership commercialize to

we're U.S. identified, as [Multiple the now investment going those and Speakers] efforts. too, Really team Michael point. over heading you this joining efforts months up to Matt, obviously, at coming their the we’ll support And see, make. he's our

we you structure test We when. haven't clear build assumptions where a that want out to We diligence. to or and given during exactly our built

Matthew Mishan

their And then, follow-up of the a does what as care a it data atherectomy say clinical better to standards for does today? that, than

Jim Clemmer

We're they've done. a It's proud good really of point, what Matt.

will who Trowbridge, Steve Matt. you, to for it handle hand me that Let

Steve Trowbridge

questions. the Hi, Matt. Thanks for

that about It data it and have calcified comes the if this But the very was well element trial out selectivity. lesion, did controlled. the It that very look was was of you unique are the highly excellent sets at what is that technology, they tissue there. their was they approval. an effective So, well run, technologies IDE laser very supported very that very, and of data of XXX(k) out from it that data an there's apart in other terms that

goes calcification it after damaging So, walls. without vessel

in it’s this We you little those a to unique to why is atherectomy. that's technology take we also a market think better technology mechanical get if take think, for the out there's further, promise current really that that have this shows opportunity into than it us articulate and that there. laser laser we And

Matthew Mishan

of -- you how given then, that from do you're in all, you in XX% the this year. segment the you a to momentum first number? last one that first see I in given squeeze quarter, underlying how or OARtrac guys Michael, are guess, growth XQ? I’ll what for hit confident to business, And where organic have your number need Jim, at on oncology oncology in big first. very And guidance Excellent. one

Jim Clemmer

Yes. question. Matt, good

And you microwave of again kind split the large I that of we acquisitions we areas know to then our growth. four two growth we parts with and you, NanoKnife year. our told have So, a this expected and two being it think

from those us in is running as four we're guidance we we So, stopped we -- that and Company seen the probably quarter-to-quarter. three than it quarter-to-quarter, we not Q you've expected, first giving don't quarterly But manage categories. softer of maybe

is We to have group guidance of part expectations we the the big you it will still hit a gave oncology that. guys. And

So, where tail are. know we know lie, headwinds our our winds we where

this we’ll think year, you have what hit front we’ll we of So, Matt. out

what to have the the really in of bigger have those plans oncology. years we last couple especially four each hope challenges we've those. of hit aspect in I We categories, And what but of is see you Matt, here, done

approval You no to and it. with to there's sold is for this trying IDE we in no years, earlier X the year NanoKnife. indication, indications Because Without every the X year look to at $X us we a it. getting have nothing by million the story really NanoKnife really $X U.S. The last granted million create market an we’re behind Matt, else FDA.

Americans approval successful that years, of one of receive, everybody the roughly if pancreatic may the with can shared the a we’ll indication market we As XX,XXX about XX% of numbers we annually go market The clear. conservative, a diagnosed with earlier the shared disease device we after this this million you And and in get approval terrible cancer. year, are with externally, hopefully, to with create we them day think, we we see. couple $XXX be of can indication

to going how of to become care. we and expand get need about standard the in a talked patients treat we're So, market,

a and been and expand also always give before. care happened and market for give treat AngioDynamics that operate the marketplace room technology, room what's and really struggling amazing to take to hasn't we'll people, So, clinicians behind an

technology. So with we're the pressure larger numbers macro understand on we it. scale, where going gave Short you, we term, Matt, we that's our have

We believe headwinds tailwinds we’ll have and we deliver. and

Operator

Please next the question. from Jason question proceed Mills is line with Genuity. Canaccord with your Our of

Jason Mills

covered joined, the broadly of long bifurcating finished just the for for out Jim, philosophy I've into force, once the broadly, to combined a sales this give XXXX? and a couple you're specifically Because know, forth I before sales the a Can times, this with and back wanted a you a done specific as and update and in the work sales idea? building give an stock -- sales will And and it start changes there on the infrastructure, with guess, lot around through to this then Eximo years and support over what force you've on us long for sales fiscal be, time, commercial while, I -- for commercial a infrastructure your force force you heading an infrastructure. So, and of several commercial to thing Eximo. you us deal, Jim, force were respect

us couple look an it you will sort what years to today, full idea after launching it like expect and give like So, of stands of what after in a that do see of look Eximo, where a Eximo way?

Jim Clemmer

Good question, Jason.

as do So, know, Company through of our has you history a gone we sales. how

direct organization. that matrix alignment don't like accountability. I I been think, know there, to We since a we've you like

You've how seen operate. that from we

So, little sales had on group interventions core on had our vascular that now We our we one laser one where focused we our delivering ago, over technologies and a you've being venous two. stated, products. and and took year force also focused seen, AngioVac

was -- months Before two split sorry. I'm it we that groups, XX ago,

we was group, split into one it two. Before

way We've clinicians out it. of And by seen as that years, side, seen is has finally numbers those value on communicate now markets. and we different you then today, and focused better the venous those to declined dedicated forces AngioVac to that we as something also sales bottomed that straight our Part two for laser the rapidly flattened of two use dedicated we predicted. have because

tested going this choosing one off Jason, here levels new product ground. as get process mentioned So, Eximo to to the theory product this sales today, route two of going of sit dedicated sales adding dedicated to earlier, current And our during diligence of route. the bags, we're or as forward, we the I we initially

we so is use that at benefits are of we that strong one today. couple message. the four the least sales physicians product make to really for now, have number years itself that of three to synergy, will look really good special, we on is also those delivering from competitors lot two, want synergy. or have sure Today so product. unique, a technology there's we market a is reasons, Number a two a feel sales of Now, at maybe the the in communicating the dedicated And lot those force their focused we'll

message. we make people want we that this dedicated So, have to can deliver sure

XXX(k). really value back as and by was the properly articulated forth, why broke Jason, really, for the set few technology, indication our of to because a ways why that communicate we're So, a special, laser either was have benefits us went do great the as use the different at they worthy physicians today so this mechanical we that end and laser, applications. to day, during granted to the just that this for what us really think tie evaluated Steve supported take At it's this. We ago, should current a it's or in of minutes of those both look

Jason Mills

what's You will to restenosis. this, strategy technology several instant plan and mentioned the atherectomy -- alike? labeling You reps Okay. respect you've Thanks large Eximo knee, But, up my have to today, really understand. about competitors, also for to talk follow couple number dedicated could get which to as size. have mentioned but question, Eximo, of and And the that that us color and entrenched knee go-to-market? application you above of didn't to this not companies the then, sales if color, and And qualitatively. helpful numbers of be has you you you're give below would was a of It with Jim. small sort you sort willing amount, players, maybe how to some do companies laser a got

cover. a geography So, positive said, has indication it’s That it having of been broad side a some on in to set. my -- the lot mind,

I’m thin. all all knee, sometimes below probably above some one be people very in trying to and be the or respects spread place to you too can other things can you different know, atherectomy, that focus As helpful. it’s the in

talk So, to could expect where about go-to-market focus you you initially? strategy,

discussed quantitatively get revenue going be taking what contribution model, are want out also, out the associated of think spending you lastly, way might fiscal sort a of you're this sales terms a There's in in with here. And back haven't of and of of what then of sort XXXX? earnings but money you're force, are the build to really I'll in yet XXXX? lot know, your much investors Eximo this to to I expectations broad if out

Jim Clemmer

get dodge it. to the And those, Let I your Jason. one. me didn't forgot first I try answer just all to question,

So, to announcement not structure we're going commercial a as today how give to people. many

that products the U.S. we by models know internal Today built, has the who’s to the Eximo, initial relationships one utilized placed Jason, of head be sales our be have will getting and dedicated. We KOLs. KOL handled in all some

in there's AngioDynamics chain levels with lasers supply at situation. want that one, the that to a the at can that the number forecast. we We customers the catheters with two, So, need expect our volume sure right our we cadence quality we make number the them; supply we’ve levels and built

things So we've up get built got to those two first.

a deliberate towards the commercialize we're thinking how we market and So, product. approach

year, our don't we're current there’ll period think make during why take of may the months at we reason revenue properly. you to so, because it trailing any not be The the this commercialize we going end we'll a year. giving guidance much. merely fiscal some sure year. update We're There of If be

EPS, we’re that as a blend, maybe we to details a then as that, but around and the numbers So, with identified how blend, spend you earlier, people this associated support expect you today probably adjustment R&D, in are what commercial, adding gave Michael one-third more two-thirds we many commercial. we towards on we’ll The year where. more do that

think we important. that's So,

different We're that. those that of two technology Above and to really, want think strong again, Again, both unique. the this competitive the can indications are knee with areas. excited going the And that's set this getting communicate by address And really, areas. after of go really granted. we're knee a And We we we indications. back agree really to think you. technology below Now, how saw we is set. the are to that you

bit deliberate us why as be opportunity to going we make to it to do that's So, Jason. that, it. being an how a do way the for right, we're one sure communicate That's way challenge, we one

lies, physicians We already interest relationships lot KOL and this utilize the product. established where of to from want a know

we So, communicate that as we do better go sure make we forward, properly.

And pathway, follows your last told and to that's future level transparent years couple we point finally, And do. of agree. of how do, to some we're we back with going going see we’ve been what having believe hopefully, investors the to you'll we're growth, very the in we really And we this portfolio, And unique to where based where marketplace want are things are do do that supplies, do our that we more commodity less well. upgrade specialized, technologies. that things

great So something our we high margins revenues Again, will over expect business we're you, behind. that The to remind Jason, very, time, entering and are update a me at level, at we growing is that Today, XX% let based a investors business looking pace. see. gross business. that bought NAMIC gross with especially margin nearly can great at no these a was what But a margin faster business, Medline double growth. very left gross upon

our build course our So, this the Jason, our investors, plan. assumptions, we during test we'll fiscal update out of as year,

If model X% as give and we of more market, in with you our you three want years go. rough to down, will think, hey, the expectations. probably line to have XX% And that's we'll use detail probably AngioDynamics a

Michael Greiner

a back quarters standalone product. we'll product, year, in anticipate we for to sometime start product And we as dilutive. a of anticipate we the four But be coming become will next accretive with as also that the this half standalone

Operator

the proceed The Please from question. Craig-Hallum. next is Hewitt with Instructions] your with line Matt question of [Operator

Matt Hewitt

think many -- the is bit devices the revenue of field? traction some which those? are how then think many start do -- how about you of at using in to can you or And Eximo are First little currently some KOLs can we show show from that a all, and base? of that base How should currently initial the least

Jim Clemmer

supply again, half because fair our reasons less dozen field So, want why being the than the question. And are chain and today. we're we one rollout, deliberate test. of in to commercial a There with

our product we're and have trusted really upon AngioDynamics, to not a years, history is quality, this been XX-year of As customers you that. was we blessing that Eximo The that. know, Company’s here at going by the really, for product had always and our designed way break and amazing. legacy We've relied

So, make also special, it it’s it's for that us really well meets ensure we important sure communicate quality but levels. how why our can works, to so it

chain sure chain trust having products not not ready. but go today, push of we're guide quarters made deliberate supply we're we’ll we catheters, to revenue. going not make them. So, the we're sure pushing, make that about, the to that the substantial on get be generate during revenue are, then, products not expecting will quality specifications have to to something field you but and When we’ll fashion. we're and a robust they any talk even in in folks, is and the trying we If we're market probably supply coming Until revenue. little with a bit to the today there our there, then our to we any really are We want

and training sales the rep programs We training have also physician ready.

think it way. believe the things we we question, going the commercialize, we competitors have also technology, there to to enter it. we’re our best adapt all We right goes So, that in when with to we of are space. got in lined our are this some up to the market make good sure But customers prepared back Jason's to

Matt Hewitt

would dedicated is little a or be would it it actually couple Is to into you the bringing how new go train Is follow-up physicians. Eximo sales And complicated people lead-in; sending or it longer question on is than How facilities be a a procedures device? something your trained them? That's regarding great. and quickly where you. out them Thank to ready perfect process? that training that? can a the get my you of That's doctor to complex or bit was

Jim Clemmer

good Another question.

even with diligence country. we’ll past the at months different training KOL in-house couple here. the training field training our combination the team and of doing we as extensive AngioDynamics; Eximo done we three over are use KOLs their field set aspects, we've around ties again, So KOL centers that believe and up; at a diligence We

So, to approach. pronged take three we're a going

need we with and out is training sales KOLs, our Eximo we of be job prestigious have the a to technology. who will really appropriate reps did at us good great what of First, KOL news really, physicians. for value that too The believe this for the the establishing really level seen build relationships again people

kind already with some of this their be to And KOLs part those said of we'd hand, and process have like raised a of you.

Eximo a that really the side. exists from today we network have So,

And of then and physicians know many don't today. these know these forget, parallel products alongside at AngioDynamics, KOLs we we right we sell

And have get we that's and We some approach with again, like involved. really know we're raised things also do product right. hand of those our measured really, to being folks our special. commercial these make their is probably and sure why deliberate But to

also want sure is go-to-market deliberate. and our to make thoughtful We

Steve Trowbridge

said, ease to But product into this a program. of time things of lot One what add thing training real of to we is feature Jim friendly. developing training our is use. a going very one our physician we're physician It's the think do materials to and put that customer of

has But that of ease laser market systems As use the a there's in is, goes think there. good for the that. Jim that said, of even like already atherectomy, current out think beyond also established this that we product using we an are level

think So, thoughtful, it's going comes also a very be complex. from terribly a platform program. isn't it But, that to we robust

Operator

for Clemmer call like Mr. to Thank now Mr. any turn closing to remarks. you. Clemmer? the back I'd

Jim Clemmer

Rob. Thanks,

exited fashion. So, QX in that you we really this a our hopefully, good morning, saw

during And this But this tailwinds know care market. know can We physicians that every who importantly, we with headwinds more maximize Company AngioDynamics. to hard we’ll our what and opportunities to remainder as portfolio where products. robust as where does We lie; with we amazing more our have risks into are do in present a the of we Company at their in talented year themselves. transform and company aligned skills a direct our immediately work hands

thing XX is We’ve us. is neat This our Adding we our and Eximo divested step months. a really acquired than one fourth technologies, today in in better a owner transformation. important we've really think has that three deal

here employees to change as our step and willingness our a and our that our customers investors the today, talked transformation. to transparent our to in we're about towards So, deal And portfolio. to talked fashion we've Eximo announce our another and proud need

a We this company we're long outcomes. morning. than in better better technologies We're the we we’ll be a a we better care, We’re will adding for were, stronger in that for this patient believe run. believe us patient joining today provide Thank you future. company

Operator

This will you. Thank conference. today's conclude

You you may lines Thank participation. time. this for disconnect at your your

AngioDynamics (ANGO) 3 Oct 192020 Q1 Earnings call transcript